Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Debt (2016 - 2025)

Historic Total Debt for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $121.2 million.

  • Lifecore Biomedical, Inc. \De\'s Total Debt rose 1929.88% to $121.2 million in Q2 2025 from the same period last year, while for May 2025 it was $121.2 million, marking a year-over-year increase of 1929.88%. This contributed to the annual value of $121.2 million for FY2025, which is 1929.88% up from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Total Debt stood at $121.2 million, which was up 1929.88% from $115.7 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Total Debt high stood at $193.9 million for Q2 2021, and its period low was $84.8 million during Q2 2023.
  • Moreover, its 5-year median value for Total Debt was $104.0 million (2024), whereas its average is $118.7 million.
  • Its Total Debt has fluctuated over the past 5 years, first tumbled by 4936.72% in 2022, then surged by 1986.15% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Total Debt stood at $166.2 million in 2021, then tumbled by 40.46% to $99.0 million in 2022, then decreased by 6.16% to $92.9 million in 2023, then increased by 19.86% to $111.3 million in 2024, then grew by 8.89% to $121.2 million in 2025.
  • Its last three reported values are $121.2 million in Q2 2025, $115.7 million for Q1 2025, and $111.3 million during Q4 2024.